Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company
Schiller
Ampronix

MRI Guidance Used in Brain Cancer Drug Injection Procedure

By Medimaging International staff writers
Posted on 19 Aug 2013
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Neurosurgeons in California are among the first in the world to utilize real-time magnetic resonance imaging (MRI) guidance for delivery of gene therapy as a potential treatment for brain tumors. Using MRI navigational technology, neurosurgeons can inject Toca 511 (vocimagene amiretrorepvec), a unique investigational gene therapy, directly into a brain tumor. This new application offers a precise way to deliver a therapeutic virus designed to make the tumor vulnerable to cancer-killing drugs.

“With chemotherapy, just about every human cell is exposed to the drug’s potential side-effects. By using the direct injection approach, we believe we can limit the presence of the active drug to just the brain tumor and nowhere else in the body,” said Clark Chen, MD, PhD, chief of stereotactic and radiosurgery and vice-chairman of neurosurgery University of California (UC) San Diego School of Medicine (USA). “With MRI, we can see the tumor light up in real time during drug infusion. The rest of the brain remains unaffected so the risk of the procedure is minimized.”

Toca 511 is a retrovirus engineered to selectively replicate in cancer cells, such as glioblastomas. Toca 511 generates an enzyme that converts an antifungal drug, flucytosine (5-FC), into the anticancer drug 5-fluorouracil (5-FU). After the injection of Toca 511, the patients are treated with an investigational extended-release oral formulation of 5-FC called Toca FC. Cancer cell killing takes place when 5-FC comes into contact with cells infected with Toca 511.

“Inevitably, almost all glioblastoma patients fail currently available therapy. The challenge, in part, is knowing if current drugs are actually penetrating the tumor. This MRI-guided approach will help us deliver this drug into the tumor directly to see if the drug is working,” said Santosh Kesari, MD, PhD, lead investigator and director of neuro-oncology at UC San Diego Moores Cancer Center (USA). “This approach may lead to new treatment options for patients battling several other types of brain cancers.”

Earlier research using gene therapy to treat brain cancer was mostly limited by the failure in delivering the drug into the brain. Under normal conditions, the brain is protected by the blood-brain barrier but this natural defense mechanism also prevents drugs from reaching the cancer cells in patients with brain tumors. Fortunately, 5-FC crosses the blood-brain barrier, and direct injection of Toca 511 into the tumor provides a means to selectively generate chemotherapy within the tumor mass.

To ensure that the adequate amount of Toca 511 is delivered to the region of the tumor, neurosurgeons at UC San Diego Health System utilize state-of-the art MRI guidance, called ClearPoint, to track the delivery and injection processes in real time. The MRI-guided process provides visual validation that the desired amount of drug is delivered into the tumor and provides physicians the ability to make adjustments to optimize the location of drug delivery. The Clearpoint technology was developed by MRI Interventions (Memphis, TN, USA).

Participants in this clinical trial must be 18 years or older; have a single, recurrent Grade 3 or 4 glioma; and have had prior surgery, radiation, and chemotherapy. The MRI-based procedure is minimally invasive and all participants of the study were discharged from the hospital one day after surgery and resumed their normal daily activity.

The phase 1 trial is evaluating the safety and tolerability of Toca 511 in combination with Toca FC (5-FC, extended-release tablets), and is being developed by Tocagen, Inc. (San Diego, CA, USA).

Related Links:

University of California, San Diego Moores Cancer Center
Tocagen
MRI Interventions



Channels

Ultrasound

view channel

New Ultrasound System Enhances Patient Care and User Experience

A new ultrasound system with innovative specialized transducers and improved image quality, intended for general imaging, women’s health, and shared service applications, has been announced. The system features improved accuracy, performance, assessment tools, advanced automation, and an enhanced user experience.... Read more

Nuclear medicine

view channel

Clinical Study Shows Added Value of Amyloid PET Imaging in the Diagnosis and Treatment of Dementia

Early-onset dementia patients could benefit from a new PET imaging agent developed by a major medical imaging vendor. The results of a clinical study showing the effectiveness of the amyloid PET imaging agent were presented at the Alzheimer’s Association International Conference (AAIC 2015) in Washington DC (USA).... Read more

General/Advanced Imaging

view channel
Image: Illustration of a new technique using Optical Coherence Tomography that could help surgeons differentiate a human brain tumor, red, from surrounding noncancerous tissue, green (Photo courtesy of  Carmen Kut, Jordina Rincon-Torroella, Xingde Li and Alfredo Quinones-Hinojosa/Johns Hopkins Medicine).

Imaging Technique Helps Safer and More Effective Removal of Brain Tumors

Researchers at the Johns Hopkins University have demonstrated a new imaging technology that could enable neurosurgeons to better differentiate between healthy and cancerous brain tissue and perform safer... Read more

Imaging IT

view channel
Image: Siemens Healthcare’s syngo.via MM Oncology facilitates compliance by clinicians to British Thoracic Society guidelines for the investigation and management of pulmonary nodules.(Photo courtesy of Siemens Healthcare).

Oncology Software Update Compliant with New BTS Guidelines

A key diagnostic imaging vendor has announced that it has modified its oncology software solution to ensure compliance with new British Thoracic Society (BTS) guidelines for lung nodule screening.... Read more

Industry News

view channel

Report Forecasts Growth of Global Computed Tomography Sector to USD 6 billion by 2019

A new report has been published that analyzes global Computed Tomography (CT) market shares, strategies, and forecasts, for the years 2013 to 2018. The report entitled “Global Computed Tomography (CT) Market Shares, Strategies, and Forecasts, 2013 to 2018,” predicts that global CT markets will continue to grow moderately... Read more
 

Events

11 Sep 2015 - 12 Sep 2015
19 Sep 2015 - 24 Sep 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.